Physician profile
Mark R Ottolin
NPI 1265525729
$2,235.43
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $183 · 2021: $244 · 2022: $771 · 2023: $380 · 2024: $14.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307 · Entertainment: $87.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.31 |
| Entertainment | $87.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $389.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $260.56 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $248.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.42 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $180.48 | 2019-2023 | Eliquis, Camzyos |
| Amgen INC. | $167.71 | 2021-2023 | Repatha |
| Opsens INC. | $147.82 | 2022-2023 | Optowire |
| Sanofi-Aventis U.S. LLC | $105.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $96.40 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $88.71 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $77.57 | 2022-2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $72.64 | 2021-2023 | Arcalyst |
| Abbott Laboratories | $44.05 | 2022-2023 | Cardiomems |
| Amarin Pharma, INC. | $43.58 | 2022 | |
| Chiesi USA, INC. | $28.64 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.46 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $17.72 | 2021 | |
| Surmodics, INC. | $17.06 | 2022 | |
| Edwards Lifesciences Corporation | $14.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ottolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.